Ali Ardekani (@AliArdMD) header
Ali Ardekani (@AliArdMD) profile picture

MD, MSc, MPH | Research Fellow @MayoClinic | Studying autoimmune diseases and the questions evidence hasn’t answered yet.

Joined December 2025
Ali Ardekani retweeted
Mayo Clinic Rheumatology just turned 100. Cortisone. A Nobel Prize. The LE cell. Generations of work that changed the field. A great symposium, alumni from near and far, and a packed dance floor with the people who make this division what it is. Here’s to the next 100. 🥂
4
8
2
57
3,050
Ali Ardekani retweeted
1/ How common is antiphospholipid syndrome (APS)? The answer is more complicated than it seems. In our new Nature Reviews Rheumatology review, we examine why defining the true epidemiologic burden of APS remains challenging. Full paper here👉: rdcu.be/M2Loes1Gqtia
2
18
53
3,244
Ali Ardekani retweeted
1/ Belimumab or anifrolumab for active nonrenal SLE? There is no head-to-head RCT, so comparative decisions rely on indirect evidence. Our network meta-analysis led by Marco Martinez and @PaulTejada8 included 11 RCTs and 8,607 patients. sciencedirect.com/science/ar…
3
13
1
47
3,544
Ali Ardekani retweeted
Which immunosuppressant has greater infection risk in #SLE? Does steroid exposure affect this risk? Check out our most recent publication! ⬇️🤓
1
1
5
147